hI @col69,
yes, industry sees the future.
But the FDA is still playing catch-up e.g. the swathe of new Guidances on cell and gene therapies over the last 2 years. And they're holding that line for us & we're right there at the head of the queue.
See, for example, the CRL they chucked to Abeona Therapeutics on Monday night for the company’s BLA for prademagene zamikeracel (pz-cel), which is a cell-based therapy under development for treatment of recessive dystrophic epidermolysis bullosa, a rare disease. No favours though. The CEO insists that the CRL says nothing about efficacy or safety but their PLI had a list of the dreaded "observations".
Cheers
GLTA(LT)H
Valuation, page-16
-
- There are more pages in this discussion • 75 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
99.0¢ |
Change
-0.035(3.41%) |
Mkt cap ! $1.130B | |||
| Open | High | Low | Value | Volume |
| $1.03 | $1.04 | 96.5¢ | $8.837M | 8.885M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 59782 | 99.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 99.5¢ | 26617 | 2 |
View Market Depth
| Last trade - 16.10pm 24/06/2024 (20 minute delay) ? |
| MSB (ASX) Chart |